Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Nivolumab (Primary) ; Cetuximab; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Feb 2018 Results published in the American Society for Radiation Oncology media release.
- 13 Feb 2018 According to an American Society for Radiation Oncology media release, results from this trial were presented at the Multidisciplinary Head and Neck Cancers Symposium (2018).
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.